Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:EPZM

Epizyme (EPZM) Stock Price, News & Analysis

Epizyme logo

About Epizyme Stock (NASDAQ:EPZM)

Key Stats

Today's Range
$1.47
$1.47
50-Day Range
$1.47
$1.52
52-Week Range
$0.41
$5.80
Volume
7,960 shs
Average Volume
3.23 million shs
Market Capitalization
$247.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Receive EPZM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Epizyme and its competitors with MarketBeat's FREE daily newsletter.

EPZM Stock News Headlines

bluebird bio Inc BLUE
Nvidia warning urgent
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Epizyme: Q2 Earnings Insights - Benzinga
See More Headlines

EPZM Stock Analysis - Frequently Asked Questions

Epizyme, Inc. (NASDAQ:EPZM) announced its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.16. The company's revenue for the quarter was up 45.8% compared to the same quarter last year.

Based on aggregate information from My MarketBeat watchlists, some other companies that Epizyme investors own include Novavax (NVAX), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), Pfizer (PFE), Applied Materials (AMAT) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/09/2021
Today
11/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EPZM
Employees
250
Year Founded
N/A

Profitability

Net Income
$-251,120,000.00
Net Margins
-391.90%
Pretax Margin
-391.80%

Debt

Sales & Book Value

Annual Sales
$37.43 million
Book Value
($0.54) per share

Miscellaneous

Free Float
128,968,000
Market Cap
$247.44 million
Optionable
Optionable
Beta
-0.41

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

This page (NASDAQ:EPZM) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners